News & Press: Breaking News

FDA Grand Rounds cites ISCT's minimal criteria for defining MSCs

Thursday, March 8, 2018  
Share |



FDA Grand Rounds cites ISCT's minimal criteria for defining MSCs

Thursday, March 8, 2018 - The FDA Grand Rounds, a webcast featuring cutting-edge research across the Agency and its impact on protecting and advancing public health, acknowledges ISCT's contributions to addressing key challenges in the field. In today's session titled Are Stem Cells Ready for Prime Time? A Look at FDA Research Advances in Regenerative Medicine, Dr. Steven Bauer put in the spotlight ISCT's position paper on minimal criteria for defining multipotent MSCs which set the industry standard to help harmonize MSC product characterization. Dr. Bauer further highlighted ISCT's related publications in Cytotherapy, the Society's official peer-reviewed scientific journal, as well as the upcoming ISCT 2018 Annual Meeting Pre-Conference Workshop on MSC Potency Assays, in which he will be presenting, in Montreal, Canada. To read more about the ISCT MSC Scientific Committee and related publications in Cytotherapy, click here.


For more information
 about the FDA Grand Rounds, click here


ISCT 2018 Pre-Conference Workshop: MSC Workshop On Potency Assays 
Wednesday, May 2 
Organized by the ISCT MSC Scientific Committee
READ MORE
Register now








 

 


© 2018 ISCT. All rights reserved. 
ISCT, and the ISCT logo are registered service marks of the International Society for Cellular Therapy.
The BEACON and lighthouse logo is a service mark of the International Society for Cellular Therapy.